Wegovy is NOT a Treatment for Hair Loss—It May Actually Cause It
Wegovy (semaglutide 2.4 mg) is not indicated for hair loss treatment and is, in fact, associated with an increased risk of hair loss as an adverse effect. The medication is FDA-approved exclusively for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities 1.
FDA-Approved Indications
Wegovy's approved uses are limited to:
- Chronic weight management in conjunction with lifestyle modifications 1
- Reduction of cardiovascular death, heart attack, and stroke risk in adults with obesity/overweight and established cardiovascular disease 2
Hair loss is explicitly listed as an adverse reaction in the FDA prescribing information, occurring in 3% of Wegovy-treated patients versus 1% with placebo 1.
Hair Loss as an Adverse Effect
The evidence consistently demonstrates that GLP-1 receptor agonists like Wegovy are associated with increased risk of hair loss, not improvement:
Quantified Risk
- 40% increased risk of non-scarring alopecia overall (OR 1.40,95% CI: 1.33-1.48) 3
- 76% increased risk of telogen effluvium specifically (aOR 1.76,95% CI: 1.34-2.32) 3
- Semaglutide shows the highest pharmacovigilance signal (ROR 2.46,95% CI: 2.14-2.83) 3
Clinical Trial Data
In the pivotal STEP trials, hair loss (alopecia) was reported in 3% of semaglutide 2.4 mg patients compared to 1% with placebo 1. In pediatric patients aged ≥12 years, hair loss occurred in 4% of Wegovy-treated patients versus 0% with placebo 1.
Real-World Evidence
A large propensity-matched cohort study found that both semaglutide and tirzepatide were associated with higher odds of nonscarring alopecia and telogen effluvium across multiple time points, with effects persisting at 3 and 5 years for semaglutide 4.
Mechanism of Hair Loss
The hair loss associated with Wegovy appears to be primarily telogen effluvium, driven by:
- Rapid weight loss: The substantial weight reduction (mean 14.9% at 68 weeks) 1 creates physiologic stress that triggers hair follicles to prematurely enter the telogen (resting) phase
- Nutritional deficiencies: Weight loss-induced micronutrient deficiency, particularly protein, iron, zinc, and biotin 3
- Metabolic stress: The rapid metabolic changes associated with significant weight reduction
Patients with hair loss outcomes had lower follow-up BMI than those without hair loss, supporting the weight loss-mediated mechanism 4.
Appropriate Hair Loss Treatments
For androgenetic alopecia, evidence-based treatments include 5:
- Topical minoxidil (5% for men, lower doses for women starting at 0.5-1.25 mg/day orally)
- Oral finasteride (for men)
- Low-level laser therapy (655-nm devices)
These require continuous use every 6 months for injectable treatments or 3 times weekly for laser therapy 6.
Clinical Recommendations
If a patient on Wegovy develops hair loss:
- Recognize this as a known adverse effect, not an indication for increased dosing
- Assess nutritional status and supplement deficiencies (protein, iron, zinc, biotin)
- Reassure that telogen effluvium is typically self-limited and reversible
- Consider slower dose titration if hair loss occurs during escalation
- Refer to dermatology for evidence-based hair loss treatments if needed
- Do not discontinue Wegovy prematurely if the patient is benefiting from weight loss and cardiovascular risk reduction—hair loss alone is not typically an indication for discontinuation 3
The paradoxical finding that some patients with central centrifugal cicatricial alopecia showed improvement (58%) 3 represents a specific scarring alopecia subtype and does not apply to typical hair loss patterns.